Status: Not yet recruiting
Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.
Participants needed: 130
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Henan Cancer HospitalUpdated: Jul 13, 2026
Eligibility criteria
1.Age ≥18 years old, both male and female are acceptable. [+6]
1.Those who are allergic to toripalimab or etoposide or have metabolic disorders... [+2]